When a single patent attracts 17 separate oppositions at the European Patent Office, it signals more than just legal friction. In the pharmaceutical market, this could signal a billion-dollar market

Novo Nordisk’s Canadian Patent CA 2601784 (Acylated GLP-1 Compounds), protecting Ozempic and Wegovy’s active ingredient, semaglutide, has lapsed. This event, linked to the non-payment of a maintenance fee, has drawn